SERVICIO MURCIANO DE SALUD

Their core work

Servicio Murciano de Salud (SMS) is the public health service of the Murcia region in southeastern Spain, operating hospitals, primary care centers, and specialized clinical units. In EU research, they contribute real-world clinical environments, patient cohorts, and healthcare demand expertise — serving as a clinical validation site for digital health tools, cancer therapies, and healthy ageing solutions. Their role bridges the gap between laboratory research and actual healthcare delivery, providing the clinical data and patient access that research consortia need to validate their innovations in practice.

What they specialise in

How they've shifted over time

SMS began its H2020 participation (2016-2019) focused on digital health infrastructure and ICT-enabled patient care — diabetes management tools, smart wearables for older adults, cloud computing platforms, and demand-driven innovation procurement. From 2020 onward, their focus shifted markedly toward clinical oncology research (colorectal and pancreatic cancer therapies, immunological approaches) and environmental health impacts (micro/nanoplastics biomonitoring). This evolution suggests the organization moved from being a test-bed for digital health tools to becoming an active clinical research partner in therapeutic and translational medicine.

SMS is trending toward deeper involvement in translational oncology and precision medicine, making them increasingly relevant for clinical trial validation and cancer research consortia.

How they like to work

SMS never coordinates projects — they consistently join as a participant or third party, contributing clinical infrastructure and patient access rather than project management. With 129 unique partners across 20 countries, they work in large, diverse consortia rather than tight bilateral collaborations. This pattern indicates an organization that is valued for what it brings to the table (clinical sites, real-world data, healthcare system access) rather than for driving research agendas, making them a low-friction partner to integrate into large consortia.

SMS has collaborated with 129 unique partners across 20 countries, indicating a broad European network built through participation in large consortia. Their connections span clinical, digital, and research organizations primarily across Western and Southern Europe.

What sets them apart

As a regional public health service rather than a university hospital, SMS offers something distinct: direct access to an entire region's healthcare delivery system, including primary care, hospital networks, and patient populations. This makes them particularly valuable for projects needing real-world clinical validation at scale, health system piloting, or demand-side input on healthcare innovation. Their dual track in both digital health deployment and oncology clinical research is unusual for a public health body of this size.

Highlights from their portfolio

• PHArA-ON
  Largest single project by funding (EUR 694,621), combining AI, smart wearables, and cloud computing for healthy ageing across multiple pilot sites.
• REVERT
  Significant clinical oncology project (EUR 343,250) developing computational frameworks and combinatorial therapies for advanced colorectal cancer.
• PLASTICHEAL
  Represents an unusual expansion into environmental health, studying micro/nanoplastics impact on human health through biomonitoring and multi-omics — a growing regulatory concern.